Literature DB >> 15036678

The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction.

S Alan McNeill1.   

Abstract

OBJECTIVES: To consider theories concerning the etiology of acute urinary retention (AUR), which may influence the outcome of a trial without catheter (TWOC), and to discuss evidence regarding the use of medical therapy in the management and secondary prevention of AUR. METHODS AND MATERIALS: A search of the literature discussing measurable parameters that may identify patients at risk for AUR and who require further intervention after initial treatment was undertaken. Studies of the effect of medical interventions for benign prostatic hyperplasia (BPH) and AUR were also identified.
RESULTS: The etiology of acute urinary retention remains unknown in many cases, which are often described as spontaneous, but catheterization remains standard management followed by a TWOC and bladder outlet surgery in those who do not void satisfactorily. Alpha-blockers (alpha(1)-adrenoreceptor antagonists) effectively reduce the symptoms associated with BPH and improve the urodynamic parameters of obstruction, without the sexual adverse events associated with the 5alpha-reductase inhibitors. They may diminish the incidence of AUR and the need for surgical intervention in symptomatic men. There is now good evidence that alfuzosin, in particular, improves the success rate of a TWOC, although other uroselective alpha-blockers have also been shown to improve the success rates of TWOC.
CONCLUSIONS: The proven effects of alpha-blockers support the hypothesis that they will increase the chances of a successful TWOC following AUR, which has now been proven in several well-designed and conducted studies. However, it is not yet clear whether these or other medical therapies have a role to play in the secondary prevention of further AUR or the need for further surgery. It is clear that certain measurable parameters may be used to identify patients at highest risk of a further episode of AUR following a successful TWOC; these patients may then be offered urgent surgical intervention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15036678     DOI: 10.1016/j.eururo.2003.10.001

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  5 in total

1.  Long term follow up of men with Alfuzosin who voided successfully following acute urinary retention*.

Authors:  V Palit; T Shah; C S Biyani; Y Elmasry; R Sarkar; G M Flannigan; R Puri
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

Review 2.  Α₁-blockers in the management of acute urinary retention secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.

Authors:  D Guang-Jun; G Feng-Bin; J Xun-Bo
Journal:  Ir J Med Sci       Date:  2014-03-06       Impact factor: 1.568

3.  A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia.

Authors:  Madhu S Agrawal; Abhishek Yadav; Himanshu Yadav; Amit K Singh; Prashant Lavania; Richa Jaiman
Journal:  Indian J Urol       Date:  2009 Oct-Dec

4.  Analysis of the treatment of two types of acute urinary retention.

Authors:  Kwangsu Park; Sang Hoon Kim; Sun Gook Ahn; Seung-Ju Lee; U-Syn Ha; Jun Sung Koh; Yong-Seok Lee; Chang Hee Han; Su Yeon Cho; Hyun Woo Kim
Journal:  Korean J Urol       Date:  2012-12-20

5.  Comparison of tamsulosin and silodosin in the management of acute urinary retention secondary to benign prostatic hyperplasia in patients planned for trial without catheter. A prospective randomized study.

Authors:  Siddangouda B Patil; Kshitiz Ranka; Vinay S Kundargi; Nilesh Guru
Journal:  Cent European J Urol       Date:  2017-06-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.